High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8426-8432
DOI: 10.1007/s00259-026-08133-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.08.2026. Verfasst von Christos Sachpekidis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Hauptthemen laut MEDLINE: Meningioma, Receptors, Somatostatin, Positron Emission Tomography Computed Tomography, Meningeal Neoplasms. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Somatostatin receptor (SSTR)-targeted PET imaging is increasingly used in the management of meningiomas. While gallium-68-labeled tracers are widely used, fluorine-18-labeled compounds may offer logistical and imaging advantages. We evaluated the feasibility and imaging characteristics of the novel SSTR ligand [¹⁸F]SiTATE PET/CT in patients with suspected or known meningioma. METHODS: Thirty-seven consecutive patients undergoing [¹⁸F]SiTATE PET/CT for suspected or known meningioma were retrospectively analyzed. Lesion detectability, tracer uptake, and tumor-to-background contrast were assessed. Semiquantitative parameters including SUVmax, SUVpeak, somatostatin receptor-expressing tumor volume (SRETV), and total lesion somatostatin receptor expression (TLSRE) were calculated. PET findings were verified by histopathology when available and otherwise by MRI follow-up as part of a composite reference standard. RESULTS: Focal tracer uptake consistent with meningioma was observed in 32/37 examinations (86.5%), identifying 69 lesions in total. Meningiomas demonstrated intense uptake (SUVmax 20.44 ± 14.54; SUVpeak 12.10 ± 8.04), significantly higher than non-meningioma lesions and reference tissues (all p < 0.01 except pituitary gland). Physiological uptake in normal brain parenchyma was minimal (SUVmax 0.11 ± 0.06), resulting in excellent tumor-to-background contrast. Mean SRETV and TLSRE were 9.81 ± 13.64 mL and 102.86 ± 193.69, respectively. No tracer-related adverse events occurred. CONCLUSION: In this retrospective cohort, [¹⁸F]SiTATE PET/CT enabled high-contrast visualization of meningiomas with intense tumor uptake and minimal background activity. These findings support the feasibility of [¹⁸F]SiTATE as an ¹⁸F-labeled SSTR tracer for meningioma imaging and justify prospective comparative evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
- Department of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
- School of Medicine, European University Cyprus, Nicosia, Cyprus.
- Department of Nuclear Medicine, German Oncology Center, Limassol, Cyprus. alexis.vrachimis@goc.com.cy.
- School of Medicine, European University Cyprus, Nicosia, Cyprus. alexis.vrachimis@goc.com.cy.
Zitieren
APA
Sachpekidis, C., Hadjitheodorou, P., Konstantinidou, K., Kyrou, K., Adamou, G., Fesas, A., Pourkhessalian, M. R., Tsechelidis, I., & Vrachimis, A. (2026). High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8426-8432. https://doi.org/10.1007/s00259-026-08133-5
Vancouver
Sachpekidis C, Hadjitheodorou P, Konstantinidou K, Kyrou K, Adamou G, Fesas A, et al. High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8426-8432. doi:10.1007/s00259-026-08133-5
BibTeX
@article{Sachpekidis2026,
author = {Sachpekidis, Christos and Hadjitheodorou, Panayiotis and Konstantinidou, Kyriaki and Kyrou, Kyriaki and Adamou, Giorgos and Fesas, Andreas and Pourkhessalian, Mohammad R and Tsechelidis, Ioannis and Vrachimis, Alexis},
title = {High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8426--8432},
doi = {10.1007/s00259-026-08133-5}
}
EUVIMED